EUR 138.8
(-0.86%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -2.02 Million EUR | -11.52% |
2022 | -1.81 Million EUR | -21.57% |
2021 | -1.49 Million EUR | 0.0% |
2020 | - EUR | -100.0% |
2019 | 4000.00 EUR | 0.0% |
2018 | - EUR | 0.0% |
2017 | - EUR | -100.0% |
2016 | 302 Thousand EUR | 30100.0% |
2015 | 1000.00 EUR | 0.0% |
2014 | - EUR | 0.0% |
2013 | - EUR | 0.0% |
2012 | - EUR | 0.0% |
2011 | - EUR | 0.0% |
2010 | - EUR | 0.0% |
2009 | - EUR | 0.0% |
2008 | - EUR | 0.0% |
2007 | - EUR | 0.0% |
2006 | - EUR | 0.0% |
2005 | - EUR | -100.0% |
2004 | 2000.00 EUR | 0.0% |
2003 | - EUR | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | -858.02 Thousand EUR | 0.0% |
2023 Q4 | 900.65 Thousand EUR | 0.0% |
2023 Q2 | 107.86 Thousand EUR | 0.0% |
2023 FY | -2.02 Million EUR | -11.52% |
2022 FY | -1.81 Million EUR | -21.57% |
2022 Q2 | - EUR | 0.0% |
2022 Q4 | -1.11 Million EUR | 0.0% |
2021 Q2 | - EUR | 0.0% |
2021 FY | -1.49 Million EUR | 0.0% |
2021 Q4 | -1.49 Million EUR | 0.0% |
2020 Q4 | - EUR | 0.0% |
2020 FY | - EUR | -100.0% |
2020 Q2 | - EUR | 0.0% |
2019 FY | 4000.00 EUR | 0.0% |
2019 Q2 | - EUR | 0.0% |
2019 Q4 | 552 Thousand EUR | 0.0% |
2018 FY | - EUR | 0.0% |
2018 Q1 | - EUR | 0.0% |
2018 Q4 | 750.00 EUR | 0.0% |
2018 Q2 | - EUR | 0.0% |
2017 Q2 | - EUR | 0.0% |
2017 FY | - EUR | -100.0% |
2017 Q4 | - EUR | 0.0% |
2017 Q1 | - EUR | 0.0% |
2016 FY | 302 Thousand EUR | 30100.0% |
2016 Q4 | - EUR | 0.0% |
2016 Q2 | - EUR | 0.0% |
2016 Q1 | - EUR | 0.0% |
2015 FY | 1000.00 EUR | 0.0% |
2015 Q3 | - EUR | 0.0% |
2015 Q4 | - EUR | 0.0% |
2015 Q2 | - EUR | 0.0% |
2015 Q1 | - EUR | 0.0% |
2014 Q4 | - EUR | 0.0% |
2014 FY | - EUR | 0.0% |
2014 Q3 | - EUR | 0.0% |
2014 Q1 | - EUR | 0.0% |
2014 Q2 | - EUR | 0.0% |
2013 Q2 | - EUR | 0.0% |
2013 Q1 | - EUR | 0.0% |
2013 Q4 | - EUR | 0.0% |
2013 Q3 | - EUR | 0.0% |
2013 FY | - EUR | 0.0% |
2012 Q1 | - EUR | 0.0% |
2012 FY | - EUR | 0.0% |
2012 Q3 | - EUR | 0.0% |
2012 Q4 | - EUR | 0.0% |
2012 Q2 | - EUR | 0.0% |
2011 Q3 | - EUR | 0.0% |
2011 FY | - EUR | 0.0% |
2011 Q4 | - EUR | 0.0% |
2011 Q2 | - EUR | 0.0% |
2011 Q1 | - EUR | 0.0% |
2010 Q4 | - EUR | 0.0% |
2010 Q1 | - EUR | 0.0% |
2010 FY | - EUR | 0.0% |
2010 Q3 | - EUR | 0.0% |
2010 Q2 | - EUR | 0.0% |
2009 Q4 | - EUR | 0.0% |
2009 Q1 | - EUR | 0.0% |
2009 Q2 | - EUR | 0.0% |
2009 FY | - EUR | 0.0% |
2009 Q3 | - EUR | 0.0% |
2008 Q1 | - EUR | 0.0% |
2008 Q3 | - EUR | 0.0% |
2008 Q2 | - EUR | 0.0% |
2008 Q4 | - EUR | 0.0% |
2008 FY | - EUR | 0.0% |
2007 Q2 | - EUR | 0.0% |
2007 Q4 | - EUR | 0.0% |
2007 Q1 | - EUR | 0.0% |
2007 Q3 | - EUR | 0.0% |
2007 FY | - EUR | 0.0% |
2006 Q1 | - EUR | 0.0% |
2006 Q2 | - EUR | 0.0% |
2006 Q3 | - EUR | 0.0% |
2006 Q4 | - EUR | 0.0% |
2006 FY | - EUR | 0.0% |
2005 FY | - EUR | -100.0% |
2005 Q4 | - EUR | 0.0% |
2005 Q3 | - EUR | 0.0% |
2005 Q2 | - EUR | 0.0% |
2005 Q1 | - EUR | 0.0% |
2004 Q4 | - EUR | -100.0% |
2004 Q2 | 500.00 EUR | 0.0% |
2004 Q3 | 500.00 EUR | 0.0% |
2004 Q1 | 500.00 EUR | 0.0% |
2004 FY | 2000.00 EUR | 0.0% |
2003 Q3 | - EUR | 0.0% |
2003 FY | - EUR | 0.0% |
2003 Q2 | - EUR | 0.0% |
2003 Q1 | - EUR | 0.0% |
2003 Q4 | 500.00 EUR | 0.0% |
2002 Q4 | - EUR | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
ABIONYX Pharma SA | 618 Thousand EUR | 428.412% |
ABIVAX Société Anonyme | 3.91 Million EUR | 151.854% |
Adocia SA | 1.38 Million EUR | 246.54% |
Aelis Farma SA | 12.35 Million EUR | 116.423% |
Biophytis S.A. | -803 Thousand EUR | -152.75% |
Advicenne S.A. | 1.42 Million EUR | 242.327% |
genOway Société anonyme | 20.1 Million EUR | 110.097% |
IntegraGen SA | 5.01 Million EUR | 140.444% |
Medesis Pharma S.A. | -2.66 Million EUR | 23.836% |
Neovacs S.A. | 29.31 Thousand EUR | 7023.603% |
NFL Biosciences SA | -56.06 Thousand EUR | -3520.122% |
Plant Advanced Technologies SA | 2.15 Million EUR | 194.271% |
Quantum Genomics Société Anonyme | -1.41 Million EUR | -43.0% |
Sensorion SA | 3.78 Million EUR | 153.581% |
Theranexus Société Anonyme | -4.63 Million EUR | 56.247% |
TME Pharma N.V. | -127 Thousand EUR | -1498.098% |
Valbiotis SA | 2.66 Million EUR | 176.071% |
TheraVet SA | -530.79 Thousand EUR | -282.366% |
Valerio Therapeutics Société anonyme | 1.26 Million EUR | 260.188% |
argenx SE | 925.49 Million EUR | 100.219% |
BioSenic S.A. | 543 Thousand EUR | 473.773% |
Celyad Oncology SA | 33 Thousand EUR | 6250.258% |
DBV Technologies S.A. | 4.15 Million EUR | 148.793% |
Galapagos NV | 203.73 Million EUR | 100.996% |
Genfit S.A. | 28.22 Million EUR | 107.191% |
GeNeuro SA | -293.8 Thousand EUR | -590.805% |
Hyloris Pharmaceuticals SA | 1.99 Million EUR | 201.785% |
Innate Pharma S.A. | -4.12 Million EUR | 50.75% |
Inventiva S.A. | 17.5 Million EUR | 111.598% |
MaaT Pharma SA | 1.65 Million EUR | 222.634% |
MedinCell S.A. | 9.28 Million EUR | 121.852% |
Nanobiotix S.A. | 36.2 Million EUR | 105.605% |
Onward Medical N.V. | -14.81 Million EUR | 86.303% |
Oryzon Genomics S.A. | 13.94 Million EUR | 114.551% |
OSE Immunotherapeutics SA | 2.22 Million EUR | 191.135% |
Oxurion NV | 104 Thousand EUR | 2051.524% |
Pharming Group N.V. | 220.1 Million EUR | 100.922% |
Poxel S.A. | 1000.00 EUR | 203058.5% |
GenSight Biologics S.A. | 3 Million EUR | 167.653% |
Transgene SA | -28.4 Million EUR | 92.855% |
UCB SA | 3.34 Billion EUR | 100.061% |
Valneva SE | 52.83 Million EUR | 103.841% |
Vivoryon Therapeutics N.V. | -3.09 Million EUR | 34.424% |